Can Influenza Cause Autoimmune Hemolytic Anemia?
Yes, influenza infection can cause autoimmune hemolytic anemia (AIHA), though this is a rare complication. While the major ACIP influenza guidelines do not list AIHA among the commonly recognized complications, case reports and mechanistic research confirm this association exists.
Evidence for the Association
The connection between influenza and AIHA is supported by both clinical case reports and experimental data:
Case report evidence demonstrates that influenza A infection can trigger warm-type AIHA in adults. A documented case involved a 67-year-old man with alcoholic liver cirrhosis who developed AIHA seven days after influenza A infection was diagnosed, with positive direct and indirect Coombs' tests confirming the diagnosis 1. This temporal relationship strongly suggests causality.
Mechanistic understanding from experimental models reveals a two-step process: First, viral infection enhances autoantibody production against red blood cells. Second, when these autoantibodies reach high levels, subsequent viral stimulation activates macrophages through gamma-interferon, leading to exacerbated erythrophagocytosis and clinical anemia 2. This explains why AIHA may not develop immediately but rather during or after the acute viral illness.
Clinical Context and Recognition
The major ACIP influenza guidelines 3, 4, 5 comprehensively list recognized influenza complications including:
- Encephalopathy
- Transverse myelitis
- Myositis
- Myocarditis and pericarditis
- Reye syndrome
Notably, AIHA is not mentioned in these authoritative guidelines, reflecting its rarity as a complication. However, recent comprehensive reviews acknowledge that viral infections, including influenza, serve as important precipitating factors for AIHA 6, 7.
Diagnostic Approach When Suspected
If you suspect influenza-triggered AIHA, follow the diagnostic workup outlined for autoimmune hemolytic anemia 8:
Essential laboratory evaluation:
- CBC showing anemia with macrocytosis
- Evidence of hemolysis: elevated LDH, low haptoglobin, elevated bilirubin, elevated reticulocyte count
- Peripheral smear for hemolysis
- Direct antiglobulin test (DAT/Coombs test) - the cornerstone diagnostic test
- Indirect Coombs test
- DIC panel to exclude other causes
Evaluate for viral causes:
- Confirm influenza infection (rapid antigen or PCR)
- Screen for other viral/bacterial causes of hemolysis (mycoplasma, etc.)
- Exclude drug-induced causes (common culprits include cephalosporins, penicillins, NSAIDs, quinolones)
Management Considerations
For Grade 1 AIHA (Hgb <LLN to 10.0 g/dL): Continue close monitoring with serial labs 8.
For Grade 2 AIHA (Hgb <10.0 to 8.0 g/dL): Hold any immunotherapy if applicable and strongly consider permanent discontinuation. Administer prednisone 0.5-1 mg/kg/day 8.
For Grade 3 AIHA (Hgb <8.0 g/dL or transfusion indicated):
- Permanently discontinue any immunotherapy
- Consider hospital admission based on clinical judgment
- Obtain hematology consultation
- Initiate prednisone 1-2 mg/kg/day (oral or IV depending on severity and rapidity of development) 8
Important Caveats
Rarity versus recognition: While influenza-associated AIHA is rare enough not to appear in major influenza management guidelines, it is well-documented in the literature. Don't dismiss hemolytic anemia in an influenza patient simply because it's uncommon.
Timing matters: AIHA may develop during acute infection or in the recovery phase, not necessarily at symptom onset. Maintain vigilance for 1-2 weeks after influenza diagnosis.
Immunocompromised patients at higher risk: Patients with underlying conditions (particularly liver disease, lymphoproliferative disorders, or autoimmune diseases) may be more susceptible to developing AIHA following viral infections 1, 7.
DAT is essential: Do not diagnose AIHA without performing a direct antiglobulin test. Clinical suspicion alone is insufficient given the overlap with other causes of hemolytic anemia.